HC Wainwright Reiterates “Buy” Rating for BiomX (NYSEMKT:PHGE)

BiomX (NYSEMKT:PHGE)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $21.00 price objective on the stock. HC Wainwright also issued estimates for BiomX’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.

BiomX Stock Performance

The stock has a market cap of $13.89 million, a PE ratio of -0.76 and a beta of 1.38. BiomX has a 52 week low of $0.48 and a 52 week high of $4.99. The business’s 50 day moving average price is $0.71 and its 200-day moving average price is $0.75. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84.

Hedge Funds Weigh In On BiomX

A number of large investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. purchased a new position in shares of BiomX during the 4th quarter valued at about $632,000. Allostery Investments LP purchased a new position in BiomX during the fourth quarter valued at approximately $470,000. Finally, JPMorgan Chase & Co. purchased a new position in BiomX during the fourth quarter valued at approximately $314,000. 40.57% of the stock is owned by institutional investors and hedge funds.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.